# A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa

> **NCT07727889** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Peking Union Medical College** · enrollment: 50 (actual)

## Conditions studied

- Hidradenitis Suppurativa (Acne Inversa)

## Interventions

- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT07727889
- **Lead sponsor:** Peking Union Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07727889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07727889, "A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07727889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*